で公開中です！ 詳しく見る
AMPE

Ampio Pharmaceuticals Inc.
AMPE

上場廃止済み

AMPEは2024年4月12日に上場廃止となりました。

ランキングに戻る
 

概要： Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development of a potential treatment for osteoarthritis of the knee ("OAK") as part of its OA-201 development program ("OA-201 program" or "OA-201").

従業員数： 6

ヘルスケア 医薬品メーカー（総合）

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 0%
ネガティブ 0%
ニュートラル
PRNewsWire
2 年前
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern.
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
ニュートラル
PRNewsWire
2 年前
Ampio Announces Voluntary Delisting and SEC Deregistration
ENGLEWOOD, Colo. , March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").
Ampio Announces Voluntary Delisting and SEC Deregistration
ニュートラル
PRNewsWire
2 年前
Ampio Provides Update on Results from Pre-IND Enabling Studies
ENGLEWOOD, Colo. , Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity.
Ampio Provides Update on Results from Pre-IND Enabling Studies
ニュートラル
PRNewsWire
2 年前
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions
ENGLEWOOD, Colo. , Jan. 11, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has reached settlements in principle in the pending securities fraud class action, Case Number 22-cv-2105-WJM-MEH (the "Securities Class Action"), and the pending consolidated derivative actions in the United States District Court for the District of Colorado, Case Number 22-cv-2803-KLM (the "Consolidated Derivative Actions").
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています